BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2475521)

  • 1. B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes.
    Matera L; Foa R; Massaia M; Giovarelli M; Veglia F; Cesano A; Lusso P; Piazza A; Santoli D
    J Clin Immunol; 1989 Jul; 9(4):329-37. PubMed ID: 2475521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B lymphocyte function in B cell chronic lymphocytic leukaemia.
    Wolos JA; Davey FR
    Br J Haematol; 1981 Nov; 49(3):395-403. PubMed ID: 6457623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of non-MHC restricted killing in cultures stimulated with B cells from chronic lymphocytic leukaemia patients: phenotypic characterization of the precursor and effector cells.
    Matera L; Foa R; Malavasi F; Bellone G; Funaro A; Veglia F; Santoli D
    Clin Exp Immunol; 1988 May; 72(2):303-8. PubMed ID: 3261664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
    Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
    Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities.
    Reyes E; Prieto A; Carrion F; Garcia-Suarez J; Esquivel F; Alvarez-Mon M
    Am J Hematol; 1997 Aug; 55(4):175-82. PubMed ID: 9257876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
    Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
    Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia.
    Foa R; Lauria F; Lusso P; Giubellino MC; Fierro MT; Ferrando ML; Raspadori D; Matera L
    Br J Haematol; 1984 Nov; 58(3):509-16. PubMed ID: 6333890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Natural killer cells lysing the blood B-lymphocytes of patients with chronic lympholeukemia].
    Khonina NA; Shubinskiĭ GZ
    Eksp Onkol; 1988; 10(4):44-6. PubMed ID: 3263265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic and functional characterization of HTLV positive neoplastic T cells cultured with interleukin-2--I. Retention of morphology, phenotype and selective cytotoxic properties in long term culture.
    Vyth-Dreese FA; de Vries JE
    Leuk Res; 1984; 8(1):1-14. PubMed ID: 6321859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous mixed lymphocyte-tumor reaction and autologous mixed lymphocyte reaction. II. Generation of specific and non-specific killer T cells capable of lysing autologous tumor.
    Uchida A; Moore M; Klein E
    Int J Cancer; 1988 May; 41(5):651-6. PubMed ID: 2966771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
    Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
    Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes.
    Fais F; Morabito F; Stelitano C; Callea V; Zanardi S; Scudeletti M; Varese P; Ciccone E; Grossi CE
    Int J Cancer; 2004 Apr; 109(3):402-11. PubMed ID: 14961579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cells in chronic leukemia. Function and markers.
    Sørskaar D; Førre O; Stavem P
    Int Arch Allergy Appl Immunol; 1988; 87(2):159-64. PubMed ID: 2973442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HL-60 myeloid leukaemia cells acquire immunostimulatory capability upon treatment with retinoic acid: analysis of the responding population and mechanism of cytotoxic lymphocyte activation.
    Geary SM; Ashman LK
    Immunology; 1996 Jul; 88(3):428-40. PubMed ID: 8774361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major histocompatibility complex-restricted recognition of autologous chronic lymphocytic leukemia by tumor-specific T cells.
    Sherman W; Liu Z; Inghirami G; Reed EF; Harris PE; Suciu-Foca NM
    Immunol Res; 1993; 12(4):338-48. PubMed ID: 7908684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia.
    Eskelund CW; Nederby L; Thysen AH; Skovbo A; Roug AS; Hokland ME
    Leuk Res; 2011 Jul; 35(7):914-20. PubMed ID: 21354618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Autologous mixed lymphocyte culture (AMLC)].
    Volk HD; Grunow R
    Allerg Immunol (Leipz); 1984; 30(2):60-73. PubMed ID: 6237558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
    Ortaldo JR; Mason AT; Gerard JP; Henderson LE; Farrar W; Hopkins RF; Herberman RB; Rabin H
    J Immunol; 1984 Aug; 133(2):779-83. PubMed ID: 6203980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective interleukin-2 production and responsiveness by T cells in patients with chronic lymphocytic leukemia of B cell variety.
    Ayanlar-Batuman O; Ebert E; Hauptman SP
    Blood; 1986 Feb; 67(2):279-84. PubMed ID: 2935203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.